Veru Inc.宣布,其用于实现高质量减重的恩博沙姆(enobosarm)与司美格鲁肽(semaglutide)联合疗法的2B期平台临床试验已完成首位患者入组。
Veru Inc.宣布,其用于实现高质量减重的恩博沙姆(enobosarm)与司美格鲁肽(semaglutide)联合疗法的2B期平台临床试验已完成首位患者入组。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.